Comparative Pharmacology
Head-to-head clinical analysis: SUPPRELIN LA versus TRIPTODUR KIT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SUPPRELIN LA versus TRIPTODUR KIT.
SUPPRELIN LA vs TRIPTODUR KIT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
SUPPRELIN LA is a sterile, biodegradable, subcutaneous implant containing histrelin acetate, a synthetic nonapeptide agonist of gonadotropin-releasing hormone (GnRH). After an initial transient increase, continuous administration results in downregulation of pituitary GnRH receptors, leading to suppressed luteinizing hormone (LH) and follicle-stimulating hormone (FSH) secretion, thereby reducing gonadal sex steroid production (testosterone in males, estradiol in females) to castrate levels.
Gonadotropin-releasing hormone (GnRH) agonist; continuous administration suppresses pituitary gonadotropin (LH and FSH) secretion, leading to decreased testosterone production in males and estrogen production in females.
50 mg subcutaneously once every 12 months (implant placed in inner upper arm).
3.75 mg intramuscularly once every 28 days.
None Documented
None Documented
Terminal half-life approximately 3-4 hours; clinical suppression of luteinizing hormone and testosterone sustained for 4 weeks due to depot formulation.
Terminal elimination half-life is 28-35 hours in healthy adults, allowing for a 4-week dosing interval. In patients with renal impairment, half-life is prolonged.
Renal: <5% unchanged; hepatic metabolism; fecal elimination of metabolites.
Renal (approximately 50% as unchanged drug and metabolites); biliary/fecal (approximately 20-30%); the remainder is metabolized.
Category C
Category C
GnRH Agonist
GnRH Agonist